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The COVID-19 pandemic has necessitated rapid adaptation of 
healthcare providers to new clinical and logistical challenges. 
Following identification of high levels of emergency department 
(ED) reattendance among patients with suspected COVID-19 
at our centre, we piloted a rapid remote follow-up service for 
this patient group. We present our service framework and 
evaluation of our pilot cohort of 192 patients. We followed up 
patients by telephone within 36 hours of their ED attendance. 
Pulse oximetry was used for remote monitoring of a subset of 
patients. Patients required between one and six consecutive 
telephone assessments, dependent on illness severity, and 23 
patients were recalled for in-person assessment. Approximately 
half of patients with confirmed or probable COVID-19 required 
onward referral for respiratory follow-up. This framework 
reduced unplanned ED reattendances in comparison with 
a retrospective comparator cohort (4.7% from 22.6%). We 
reproduced these findings in a validation cohort with a high 
prevalence of acute COVID-19, managed through the clinic in 
September–October 2020, where we identified an unplanned 
ED reattendance rate of 5.2%. We propose that rapid remote 
follow-up is a mechanism by which ambulatory patients can 
be clinically supported during the acute phase of illness, with 
benefits both to patient care and to health service resilience.
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Clinical problem
Health systems globally have faced enormous clinical and 
logistical challenges during the COVID-19 pandemic.1 The decision 
to admit or discharge a patient with suspected COVID-19 from 
the emergency department (ED) is a key point in an individual 
patient journey, with implications for outcome, infection control 
and hospital capacity. In the context of an emerging infectious 
disease such as COVID-19, uncertainty about trajectory and risk of 
respiratory deterioration in the second week of illness2 contributes 
to challenges surrounding safe discharge.
Outcomes of a cohort of patients discharged from the ED 
with suspected COVID-19 during April 2020 were evaluated by 
colleagues at our centre.3 They identified a high ED reattendance 
rate (45 of 199 patients; 22.6%), with a significant minority 
of patients requiring admission (12 of 199; 6.0%). Structured 
telephone follow-up identified many patients with persistent 
breathlessness following acute illness, in keeping with reports of 
‘long-tail’ COVID-19 symptoms4,5 and with evidence from other 
respiratory viruses.6–8 These results prompted us to identify a 
clinical need for a remote follow-up service for patients discharged 
from the ED with suspected COVID-19. Our aims were that this 
service would support patient self-management in the community, 
proactively identify deteriorating patients requiring reassessment, 
and form a pathway via which patients with persistent symptoms 
could be referred into specialist follow-up. We also devised the 
service as a mechanism by which patients who were tested for 
SARS-CoV-2 during ED attendance could be provided with their 
test result, contextualised with clinical and infection control advice.
We present the framework of our service, evaluation of the 
cohort of patients managed during its pilot period in May–June 
2020, and evaluation of a second validation cohort managed in 
a time of rising COVID-19 community prevalence in September–
October 2020. This analysis was conducted as a retrospective 
service evaluation project and therefore individual consent 
and formal ethical review were not required, as per assessment 
using the NHS Health Research Authority system (HRA) decision 
tool.9 The project was registered as a service evaluation with the 
Hospital for Tropical Diseases Research and Audit Committee, 
and the pathway was approved by the University College London 
Hospitals (UCLH) COVID-19 clinical guidelines committee.
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Proposed solution
Our rapid remote follow-up pathway is shown in Fig 1. Patients with 
suspected COVID-19 were identified as eligible for discharge by ED 
clinicians based on specified criteria. A subset of these patients were 
eligible for provision of a pulse oximeter, on the basis of higher-risk 
clinical features. All patients were given an information leaflet with 
advice on infection control, self-monitoring, indications to reattend for 
assessment, and a contact phone number for clinical advice in hours.
The follow-up clinic was led by an infectious diseases specialist 
registrar and ran 7 days a week. An electronic health records 
system (EHRS) report was used daily to identify patients who 
had been discharged from the ED in the previous 36 hours with a 
COVID-19-related clinical code, and/or who had been tested for 
SARS-CoV-2 during attendance. This list was triaged and patients 
scheduled for a telephone follow-up appointment within 36 hours 
of attendance. A standardised electronic proforma was used for 
clinical documentation of assessments.
On the basis of their telephone assessment and test results, 
the clinic registrar allocated patients into diagnosis categories of 
confirmed/probable COVID-19, unlikely COVID-19 or uncertain 
Fig 1. Rapid remote follow-up pathway. CRP = C-reactive protein; ED = emergency department; HR = heart rate; RR = respiration rate.
ED attender with suspected COVID-19
>  Safe for discharge from ED (all of): O
2
 saturation ≥94% and exercise desaturation <2%, HR < 110, RR <23
>  Criteria for considering pulse oximeter (any of): CRP >50; RR >20; O
2
 saturation 94 or 95%; exercise 
desaturation >2%; typical significant COVID-19 radiological abnormalities
EHRS report
>  Identifies all ED discharges with COVID-19-related diagnosis and/or tested for SARS-CoV-2 in the ED
>  Clinic doctor triages list and schedules patients for follow-up call within 36 hours of attendance
Telephone assessment
Patient calls into clinic via safety-net number 
provided in ED or during follow-up
COVID-19 confirmed or probable (determined on 
swab result and/or clinical history and other results)
High risk of 
deterioration 
(based on day of 
illness and clinical 
features)
>  Further follow-up 
call(s) scheduled
Low risk of 
deterioration
>  Discharged from 
regular follow-






>  Recall for 
face-to-face 
assessment
COVID-19 unlikely or uncertain (determined on 
swab result, clinical history and other results)
>  Ensure 
appropriate 
follow-up plan in 
place 
>  Discharge from 
COVID-19 
service
All patients with confirmed or probable COVID-19 with radiological changes or ongoing shortness of breath at 
day 28 – referred to long-term respiratory follow-up
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diagnosis. Those with confirmed/probable COVID-19 were 
categorised as being at low or high risk of deterioration. Patients 
were scheduled for further follow-up telephone calls as judged 
necessary by the clinician on the basis of this assessment. Low-risk 
patients were not proactively followed up, but were encouraged to 
use the clinic’s ‘safety-net’ phone number if needed.
Both scheduled and ‘patient-activated’ calls made to the clinical 
contact number could trigger a recall for face-to-face review if 
clinically indicated. Patients were assessed in a ‘hot’ or ‘cold’ 
clinical area of the hospital, dependent on their duration of illness 
and potential infectivity if <14 days from onset. Patients with 
symptoms persisting beyond 28 days, or who had COVID-19-
associated radiological changes at their initial attendance, were 
referred to a specialist COVID-19 respiratory clinic at our centre 
for onward management. Patients with alternative diagnoses, 
or those who required non-COVID-19-related investigation, were 
referred for alternative follow-up as indicated.
Results to date
We evaluated a cohort of 192 patients with suspected COVID-19 
who were managed through our remote follow-up service during its 
pilot period (27 April – 3 June 2020). This comprised clinical activity 
of a median of 9 (range 2–17) telephone clinic appointments per 
day (supplementary material S1; Fig S1). Background demographics 
and clinical characteristics at ED presentation are shown in Table 1. 
Clinical features were consistent with mild illness, with vital signs 
within the normal range and low serum C-reactive protein levels 
(Table 1). Patients tended to present late in disease, with a median 
day of illness at presentation of 13 days (interquartile range (IQR) 
3–28 days). The majority of patients fell into a low-risk (53.6%) or 
medium-risk (35.9%) category for developing moderate/severe 
COVID-19, on the basis of age and comorbidities (supplementary 
material S1; Table S1).
The majority of patients (79.7%) were tested for SARS-CoV-2 in the 
ED (Table 1). Reasons for not testing patients included an existing 
positive result from another service or presentation >28 days 
following symptom onset. Test results and diagnoses are shown 
in supplementary material S1, Table S2. Twelve new COVID-19 
diagnoses were made, alongside nine patients who had previously 
tested positive. A diagnosis of probable COVID-19 was made in 
a further 62 patients on the basis of their clinical characteristics, 
despite not being tested or having a negative test result from ED 
presentation (recognising the inherent limitations in test sensitivity 
Table 2. Cohort trajectories
All patients,  
n=192
Confirmed or probable 
COVID-19, n=83
Unlikely or uncertain 
COVID-19, n=109
Discharged with pulse oximeter, n (%) 8 (4.2) 6 (7.2) 2 (1.8)
Using own pulse oximeter, n (%) 21 (10.9) 17 (20.5) 4 (3.7)
Number of telephone encounters, median (range) 1 (1–6) 1 (1–6) 1 (1–4)
Planned reattendances, n (%) 23 (12.0) 18 (21.7) 5 (4.6)
Planned reattendances leading to admissions, n (%) 5 (2.6) 4 (4.8) 1 (0.9)
Unplanned reattendances, n (%) 9 (4.7) 6 (7.2) 3 (2.8)
Unplanned reattendances leading to admissions, n (%) 2 (1.0) 2 (2.4) 0 (0.0)
‘Planned reattendances’ refers to patients who were recalled for face-to-face assessment by the telephone clinic. ‘Unplanned reattendances’ refers to patients who 
reattended without prompting.
and the effect of time after illness onset).10 As described above, 
diagnoses of probable COVID-19 were made by the infectious 
diseases clinician during telephone follow-up assessments. Either 
confirmed or probable COVID-19 was diagnosed in a cumulative 
43.2% of the overall cohort.
Follow-up trajectories are shown in Table 2, stratified into 
confirmed/probable COVID-19 versus unlikely COVID-19 / uncertain 
diagnosis. A small number of patients (4.2%) were provided 
with pulse oximeters on discharge, and other patients (10.9%) 
reported using self-sourced pulse oximeters for home monitoring. 
The median number of telephone assessments per patient was 1 
Table 1. Pilot cohort: patient demographics 
and characteristics at emergency department 
presentation, 27 April – 3 June 2020
Demographics All patients, 
n=192
Age, years, median (IQR) 43 (32–55)
Female, n (%) 96 (50.0)
Never smoker, n (%) 97 (50.5)
HCW or recent healthcare exposure, n (%) 45 (23.4)
Lives alone, n (%) 55 (28.6)
Characteristics
Day of illness, median (IQR) 13 (3–28)
Oxygen saturation, %, median (IQR) 98 (97–99)
Respiratory rate, breaths per minute,  
median (IQR)
18 (17–19)
C-reactive protein, mg/L, median (IQR) 2.2 (0.7–11.0)
Chest X-ray abnormality (any), n (%) 43 (22.4)
D-dimer, μg/L, median (IQR)a 355 (210–585)
CTPA positive for pulmonary embolismb 2/22
Swabbed for SARS-CoV-2 in ED, n (%) 153 (79.69)
Missing data: smoking status (10), household status (10), C-reactive protein 
(16), oxygen saturation (6), respiratory rate (5) and day of illness (5). Twenty 
patients did not have chest X-rays at ED attendance. aD-dimer was checked 
in 80 patients (low risk 52; medium risk 22; high risk 6); b22 patients had 
CTPAs (low risk 10; medium risk 9; high risk 3). CTPA = computed tomography 
pulmonary angiography; HCW = healthcare worker; IQR = interquartile range.
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(range 1–6), demonstrating that many low-risk patients could be 
managed with one follow-up assessment alongside communication 
of their test result. During the course of follow-up, 23 patients 
(12%) were recalled for face-to-face assessments (referred to as 
planned reattendances in Table 2). The majority of these patients 
(18/23) were within the confirmed/probable COVID-19 group, and 
five recalls led to hospital admissions. 
We retrospectively reviewed our EHRS to determine whether 
patients had ‘unplanned reattendances’ to ED in relation to 
their suspected COVID-19 illness (ie attendances that were 
not prompted by the telephone follow-up clinic), either during 
or after follow-up (Table 2). We identified nine unplanned ED 
reattendances (4.7%), of which two led to admissions. Of note, six 
reattending patients had been uncontactable during attempted 
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17 (8.9) 7 (8.4) 10 (9.2)
ED reattendance in comparison with our historical comparator 
cohort (22.6%).3 When asked during assessments, a small number 
of patients (5 of 192) reported contact with their GP or NHS 111 
during follow-up.
There were no deaths within the cohort. Ongoing care 
destinations are shown in Table 3. Of patients in the confirmed/
probable COVID-19 group, the majority required ongoing specialist 
care: 49.4% were referred to the respiratory COVID-19 clinic and 
8.4% were referred to other secondary care clinics. Reasons for 
referral to the respiratory clinic were persistent breathlessness or 
other respiratory symptom in 26 patients (63.4%) and abnormality 
in chest imaging on initial presentation in 15 patients (36.6%). 
The majority of patients in the group with unlikely COVID-19/ 
uncertain diagnosis were referred back to their GP (88.1%), 
with the remainder of these patients requiring referral to other 
secondary care clinics for management of alternative diagnoses. 
Three patients from this group, for whom a diagnosis of 
COVID-19 was felt unlikely but possible and who had persistent 
breathlessness, were referred to the respiratory COVID-19 clinic 
for further investigation. Formal patient feedback using an SMS 
survey (sent ≥3 weeks after initial attendance) had a low uptake 
of <5%. Informal feedback from patients and other stakeholders 
such as ED clinicians and GPs was positive. 
Recognising that the prevalence of acute COVID-19 (diagnosed 
at the relevant ED attendance) was low in our pilot cohort, we 
sought to remeasure our reattendance metrics in a validation 
cohort from a time of higher COVID-19 incidence. Rates of 
acute COVID-19 diagnosis in patients managed through the 
service remained low throughout June–August 2020, but rose in 
September and October 2020 (supplementary material S1; Fig S2) 
when rates of positive swabs were 22.5% and 53.7% respectively.
We carried out a focused evaluation of patients managed 
through the service from 1 September – 23 October 2020 (n=134, 
Table 4), of whom 35% (n=47) had a positive swab for SARS-
CoV-2. Median age, gender distribution and oxygen saturations 
were similar to those of the initial cohort, while median C-reactive 
Table 4. Validation cohort characteristics and trajectories; emergency department attendances 1 September – 
23 October 2020
Demographics All patients,  
n=134
COVID-19 positive,  
n=47
COVID-19 negative or 
swab not done, n=87
Age, median (IQR) 41 (28–56) 47 (29–60) 37 (27–53)
Female, n (%) 68 (50.7) 23 (48.9) 45 (51.7)
Characteristics at ED presentation
Oxygen saturation, %, median (IQR) 97.5 (96–99) 96 (95.5–98) 96 (96–98)
C-reactive protein, mg/L, median (IQR) 8.4 (1.3–25.4) 11 (3.7–24.7) 6.9 (0.6–25.6)
Cohort trajectories
Number of telephone encounters, median (range) 1 (1–8) 2 (1–8) 1 (1–5)
Total reattendances, n (%) 12 (9.0) 7 (14.6) 5 (5.7)
Planned reattendances, n (%) 5 (3.7) 3 (6.2) 2 (2.3)
Planned reattendances leading to admissions, n (%) 2 (1.5) 2 (1.3) –
Unplanned reattendances, n (%) 7 (5.2)a 4 (8.3)b 3 (3.4)
Unplanned reattendances leading to admissions, n (%) 3 (2.2) 3 (6.2) –
Missing data: oxygen saturation (2) and C-reactive protein (12). a of which five had been uncontactable by the telephone clinic; b of which two had been uncontactable; 
ED = emergency department; IQR = interquartile range.
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protein level was higher (8.4 mg/L vs 2.2 mg/L; p=0.0005, Mann–
Whitney U test). Again, we determined reattendances to ED, and 
stratified these into planned (prompted by the follow-up service) 
and unplanned. There were 12 reattendances, of which 5 (3.7%) 
were planned and 7 (5.2%) were unplanned (Table 4). Focusing 
on patients who had tested positive for COVID-19, there were 3 
(6.2%) planned reattendances of which 2 led to admissions, and 
4 (8.3%) unplanned reattendances of which 3 led to admissions. 
The unplanned reattendance rates of 5.2% (total cohort) and 
8.3% (COVID-19-positive cohort) were comparable to the 4.7% 
measured in our pilot cohort and remained lower than the 22.6% 
in the historical comparator cohort.3
Future directions
We note that similar remote follow-up pathways or ‘virtual wards’ 
have been successfully developed at a number of UK centres for 
management of COVID-19, incorporating innovations such as use 
of point-of-care ultrasound in the community to inform remote 
assessments.11 North American centres have extended remote 
monitoring of COVID-19 patients to automated text message 
monitoring systems, able to activate clinician telemedicine 
assessments when necessary.12
We suggest that these pathways may contribute to hospital 
resilience during further potential pandemic waves. When 
we retrospectively compared our cohort with the cohort who 
attended the ED at our centre during April 2020 (prior to initiation 
of the follow-up clinic),3 we identified a decrease in unplanned 
ED reattendances: 4.7% versus 22.6%. We recognised that this 
historical comparison was limited by the lower prevalence of acute 
COVID-19 during the tail of the spring wave of the pandemic. 
However, we validated our lower unplanned reattendance rates, in 
a second cohort managed by the remote follow-up service during 
the upturn of the autumn–winter pandemic wave (35% of whom 
tested positive for COVID-19), who had an unplanned reattendance 
rate of 5.2% (8.3% in those testing positive for COVID-19).
We also propose that rapid follow-up still provides an important 
service to patients who test negative for COVID-19: ensuring rapid 
communication of test results, allowing assessment of whether 
a diagnosis of ‘probable COVID-19’ should be made despite a 
negative test result, or contributing to identification of an alternative 
diagnosis and ensuring that patients are referred appropriately. 
In this way, rapid remote follow-up provides care for unselected 
patients presenting with symptoms suspicious of COVID-19, and 
ensures quality of ongoing management (and therefore fewer 
unplanned ED reattendances) regardless of test result.
There are other limitations to our findings; there may be other 
contributing factors to lower reattendance rates in more recent 
cohorts, for example increased public knowledge about COVID-19 
symptoms or increased accessibility of other community healthcare 
providers. Nonetheless, our evaluation suggests that rapid 
remote follow-up is a framework by which repeated unplanned 
ED reattendance could be reduced, by ensuring that patients are 
adequately supported in the community. This could be applicable 
to both COVID-19 and other conditions. Studies have shown that 
telephone follow-up can identify and address unmet health needs for 
older patients discharged from the ED setting,13 and improves patient 
satisfaction in unselected cohorts discharged from medical wards.14
Our evaluation has identified aspects of our practice to build 
on. Our qualitative experience was that pulse oximetry enhanced 
telephone assessment of patients, particularly when coupled with 
simple exercise tests such as 1 minute of sit-to-stand.15 A cumulative 
total of 15.1% of patients in our cohort were using home pulse 
oximetry, but clinician uptake of offering pulse oximetry to 
patients on discharge from the ED was low (4.2% of patients used 
provided oximeters, 10.9% used their own device). We required ED 
clinicians to apply specific criteria identifying patients as eligible 
for provision of a pulse oximeter. We note that other ambulatory 
COVID-19 services have provided all patients with pulse oximetry,11 
and minimising clinical gatekeeping could enhance uptake of this 
inexpensive but clinically valuable intervention.
As the service became established, we began to take direct 
referrals from GPs managing patients with suspected COVID-19 in 
the community, and enhancing this alternative referral pathway 
may be a valuable mechanism by which primary and secondary 
care can provide joined-up care for ambulatory patients. Many 
patients required onward referral to secondary care clinics due to 
persistent symptoms. This may indicate that patients attending 
the ED were more likely to lie at the moderate–severe end of 
the COVID-19 spectrum, even if they did not require admission, 
alongside the fact that some initial ED attendances were due to 
‘long-tail’ persistent COVID-19 symptoms.
We propose that the framework we have developed for rapid 
remote follow-up represents a robust mechanism by which acute 
hospitals can safely manage patients with suspected COVID-19 in 
the community following ED discharge. We suggest that sharing the 
learning from development of such services across UK centres should 
be a key consideration in preparedness for further pandemic waves. ■
Supplementary material
Additional supplementary material may be found in the online 
version of this article at www.rcpjournals.org/clinmedicine:
S1 – Supplementary tables and figures.
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